Financial Performance - The company's operating revenue for 2020 was ¥1,111,802,396.45, a decrease of 43.77% compared to ¥1,977,206,434.29 in 2019[11]. - The net profit attributable to shareholders was -¥359,496,105.33, an improvement of 82.39% from -¥2,041,890,393.46 in the previous year[11]. - The basic earnings per share for 2020 was -¥0.37, improving by 82.46% from -¥2.11 in 2019[11]. - The weighted average return on equity was -14.62%, an improvement from -57.92% in the previous year[11]. - The company reported a significant decrease in net profit for the last three accounting years, indicating ongoing challenges in maintaining operational viability[11]. - The company reported a revenue of ¥1,111,802,396.45, a decrease of 43.77% compared to the previous year, and a net profit attributable to shareholders of -¥359,496,105.33, which represents a reduction in losses of ¥1,682,394,288.13[23]. - The company reported a net profit of -359,496,105.33 CNY for 2020, with a profit margin of 0.00%[73]. - The company's net profit for 2020 was -360,659,985.13 CNY, compared to -2,042,936,120.94 CNY in 2019, showing a significant reduction in losses[190]. Cash Flow and Investments - The net cash flow from operating activities was ¥80,705,132.34, representing a 7.81% increase from ¥74,861,078.98 in 2019[11]. - The net cash flow from investment activities improved by 35.57% compared to the previous year, despite a significant decrease in cash inflow from investment activities by 81.04%[38]. - The net cash flow from financing activities was CNY 579,999,865.38, a decrease from CNY 703,289,724.02 in the previous year[197]. - The total cash inflow from investment activities was CNY 95,036,551.66, significantly lower than CNY 501,314,254.39 in the previous year[197]. - The company reported a total cash and cash equivalents increase of CNY 136,042,744.72, contrasting with a decrease of CNY 36,149,528.44 in the previous year[197]. Assets and Liabilities - The total assets at the end of 2020 were ¥4,977,076,111.43, an increase of 5.94% from ¥4,698,048,449.36 at the end of 2019[11]. - The total liabilities increased to CNY 2,671,751,837.82 in 2020, up from CNY 2,032,064,190.62 in 2019, indicating a rise of approximately 31.5%[183]. - Long-term borrowings increased significantly by 15.52% to ¥1,813,955,268.27 in 2020 from ¥983,211,736.24 in 2019[41]. - The company's total assets reached CNY 6,037,807,723.98 in 2020, compared to CNY 5,434,022,590.83 in 2019, marking a growth of 11.1%[189]. - The equity attributable to shareholders decreased to CNY 4,180,578,339.73 in 2020 from CNY 4,280,307,833.30 in 2019, a decline of 2.3%[187]. Research and Development - The company has a total of 42 invention patents, 64 utility model patents, and 2 design patents, with 2 invention patents currently under review[22]. - The company is advancing the Phase III clinical trial of its new drug, Succinyl-8-hydrogen-aminocarbamate tablets, with 600 cases enrolled to date[24]. - R&D investment decreased by 34.04% to ¥57,916,518.70 in 2020 from ¥87,805,670.72 in 2019, while the proportion of R&D investment to operating income increased to 5.21% from 4.44%[37]. - The company aims to enhance its R&D capabilities by integrating chemical, biological, and innovative drug development systems[22]. Market and Industry Challenges - The company faces risks including industry policy changes, rising production costs, and impacts from the COVID-19 pandemic[2]. - The pharmaceutical industry is undergoing significant reforms, with policies such as "volume-based procurement" and improvements in medical insurance payment methods shaping the market landscape[19]. - The company faced challenges in sales volume due to policy adjustments and the impact of the COVID-19 pandemic, leading to a decline in revenue and net profit[18]. Corporate Governance and Compliance - The company has established a comprehensive internal control system to protect the rights of shareholders and creditors[110]. - The independent directors attended 100% of the board meetings and provided constructive opinions on major matters such as profit distribution and related transactions[161]. - The company maintains independence from its controlling shareholder in terms of business, personnel, assets, organization, and finance, ensuring a complete and independent operational system[155]. - The company has established measures to ensure compliance with securities laws and industry policies regarding competition[77]. Social Responsibility and Environmental Compliance - The company donated a total of 224 boxes of "Transfer Factor Oral Liquid" to key epidemic prevention institutions during the COVID-19 pandemic, supporting public health efforts[111]. - The company invested 8.2 million yuan to build a new wastewater treatment plant with a capacity of 1000 tons per year, which has been operational since 2018[115]. - The company has implemented an environmental monitoring system to ensure compliance with pollution discharge standards[121]. - The company has not experienced any major safety incidents or environmental violations during the reporting period[111]. Shareholder Information - The total number of shareholders at the end of the reporting period was 52,089[125]. - Beijing Jinshang pledged to strictly adhere to regulations and not exploit its major shareholder status to harm the company or other shareholders' rights[75]. - The company has not reported any changes in its controlling shareholder during the reporting period[130]. - The company did not engage in any repurchase transactions among the top 10 shareholders during the reporting period[127].

通化金马药业集团股份有限公司 2020 年第三季度报告全文 通化金马药业集团股份有限公司 2020 年第三季度报告 2020 年 10 月 1 通化金马药业集团股份有限公司 2020 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人张玉富、主管会计工作负责人于军及会计机构负责人(会计主管 人员)耿兰声明：保证季度报告中财务报表的真实、准确、完整。 2 通化金马药业集团股份有限公司 2020 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | |-----------------------------------------------------|-----------------------------------|-------------------------|----------- ...

通化金马药业集团股份有限公司 2020 年半年度报告全文 通化金马药业集团股份有限公司 2020 年半年度报告 2020 年 08 月 1 通化金马药业集团股份有限公司 2020 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人张玉富、主管会计工作负责人于军及会计机构负责人(会计主管 人员)耿兰声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 | --- | |-------------------------------------------------------------------------| | | | 公司可能面临行业政策变化风险、生产要素成本上涨的风险、研发风险、 | | 新冠肺炎疫情影响等，详细内容已在本报告第四节"经营情况讨论与分析（十）、 | | 公司面临的风险和应对措施"部分予以描述，敬请广大投资者注意投资风险。 | | 公司计划不派发现金红利，不送红股，不以公积金转增股本 ...

证券代码：000766 证券简称：通化金马 公告编号：2020-57 通化金马药业集团股份有限公司 关于参加 2020 年吉林辖区上市公司投资者网上集体接待日活动的 公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，通化金马药业集团股份有限公司（以下简 称"公司"）将参加由吉林证监局、吉林省证券业协会、深圳市全景网络有限公司共 同举办的"提高公司质量 做受尊敬的上市公司--2020 年吉林辖区上市公司投资者网 上集体接待日"活动，现将有关事项公告如下： 本次集体接待日活动将通过深圳市全景网络有限公司提供的互联网平台举行， 投资者可以登陆"全景·路演天下"网站（http://rs.p5w.net）参与公司本次投资 者集体接待日活动,时间为 2020 年 8 月 21 日（周五）15:30 至 17:00。 届时公司总经理、董事会秘书、财务总监等将通过网络在线问答互动的形式， 与投资者就公司治理、发展经营情况、融资情况和可持续发展等投资者关注的问题 进行交流。期间，公司高管将全程在线，实时回答投资者的提问。 欢迎广大投资者积极参 ...

通化金马药业集团股份有限公司 2019 年年度报告全文 通化金马药业集团股份有限公司 2019 年年度报告 2020 年 04 月 1 通化金马药业集团股份有限公司 2019 年年度报告全文 第一节重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人战红君、主管会计工作负责人于军及会计机构负责人(会计主管 人员)耿兰声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本年度报告涉及公司未来发展展望、经营计划等前瞻性陈述，不构成对投 资者的实质承诺，请投资者认真阅读，注意投资风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 通化金马药业集团股份有限公司 2019 年年度报告全文 目录 | --- | --- | |-------------------------------------------------------------------------------------|-------| | | | | 第一节 ...

通化金马药业集团股份有限公司 2019 年年度报告全文 通化金马药业集团股份有限公司 2019 年年度报告 2020 年 04 月 1 通化金马药业集团股份有限公司 2019 年年度报告全文 第一节重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人战红君、主管会计工作负责人于军及会计机构负责人(会计主管 人员)耿兰声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本年度报告涉及公司未来发展展望、经营计划等前瞻性陈述，不构成对投 资者的实质承诺，请投资者认真阅读，注意投资风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 通化金马药业集团股份有限公司 2019 年年度报告全文 目录 | --- | --- | |-------------------------------------------------------------------------------------|-------| | | | | 第一节 ...

Financial Performance - The company's operating revenue for Q1 2020 was ¥151,452,899.87, a decrease of 63.01% compared to ¥409,397,546.32 in the same period last year[3] - The net profit attributable to shareholders was -¥44,419,586.26, representing a decline of 187.21% from ¥50,931,985.61 in the previous year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥56,565,311.12, a decrease of 239.04% compared to ¥40,683,222.82 last year[3] - Operating revenue decreased by 63.01% due to the impact of the pandemic on sales[9] - The net profit for Q1 2020 was a loss of ¥44,659,282.41, compared to a profit of ¥50,644,468.36 in Q1 2019, indicating a shift in financial performance[26] - The net profit for the first quarter of 2020 was CNY 14,241,505.68, a significant decrease compared to CNY 87,921,660.43 in the same period last year[30] - Basic and diluted earnings per share for Q1 2020 were both -¥0.0460, compared to ¥0.0527 in the previous year[28] - The total comprehensive income for the first quarter was CNY 14,241,505.68, compared to CNY 87,921,660.43 in the previous year[31] Cash Flow - The net cash flow from operating activities improved to ¥26,046,278.34, a 140.84% increase from -¥63,776,462.86 in the same period last year[3] - Net cash flow from operating activities increased by 140.84% due to a reduction in payments for goods and prepayments compared to the same period last year[9] - The net cash flow from investing activities decreased by 841.59% due to the acquisition of a 15% stake in Longmei Hospital[9] - The net cash flow from financing activities increased by 245,547.21% due to an increase in loans compared to the same period last year[9] - The cash outflow from investing activities was CNY 494,586,818.61, compared to CNY 337,440,947.98 in the same period last year[33] - The net cash flow from investing activities was -489,480,070.21 CNY, indicating significant cash outflows related to investments[36] - The net cash flow from financing activities was 182,702,800.25 CNY, primarily driven by cash received from borrowings of 198,750,000.00 CNY[36] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,658,224,363.33, an increase of 20.44% from ¥4,698,048,449.36 at the end of the previous year[3] - The total liabilities reached CNY 3,036,899,387.00, up from CNY 2,032,064,190.62, which is an increase of approximately 49.4%[20] - The company's equity attributable to shareholders decreased to CNY 2,586,511,331.23 from CNY 2,630,930,917.49, a decline of about 1.7%[21] - The total liabilities as of the end of Q1 2020 were ¥2,138,654,372.63, compared to ¥1,153,714,757.53 at the end of the previous year, indicating increased leverage[24] - The total current liabilities amounted to CNY 911,454,123.66, slightly up from CNY 905,034,652.99, indicating a marginal increase of about 0.5%[20] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 46,599[5] - The largest shareholder, Beijing Jinshang Alliance Investment Management Co., Ltd., held 24.98% of the shares[5] - The company did not engage in any repurchase transactions during the reporting period[6] Investments and Acquisitions - The company plans to acquire 85% stakes in Jixi Jikuang Hospital and Shuangyashan Shuangkuang Hospital for an initial consideration of 153 million yuan[10] - Prepayments surged by 1489.89% due to the acquisition of a 15% stake in Longmei Hospital and prepayments for the acquisition of funds from Heilongjiang Property Exchange[9] - Goodwill increased by 92.23% as a result of the acquisition of Harbin Shengtai Pharmaceutical's stake in Harbin Cezhan Pharmaceutical[9] Research and Development - Research and development expenses rose by 128.63% due to increased investment in R&D projects[9] - Research and development expenses increased to ¥8,425,926.98 in Q1 2020, up from ¥3,685,405.11 in the same period last year, highlighting a focus on innovation[25] Government Support - The company received government subsidies amounting to ¥14,840,456.33 during the reporting period[4] Financial Structure - The company's cash and cash equivalents increased to CNY 638,244,758.35 from CNY 150,219,230.03, reflecting a growth of approximately 325.5%[22] - The company incurred a credit impairment loss of CNY -6,168,475.17 during the quarter[30] - The company has a long-term debt of 983,211,736.24 CNY, indicating a significant leverage position[40]

通化金马药业集团股份有限公司 2019 年第三季度报告全文 通化金马药业集团股份有限公司 2019 年第三季度报告 2019 年 10 月 1 通化金马药业集团股份有限公司 2019 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人战红君、主管会计工作负责人于军及会计机构负责人(会计主管 人员)耿兰声明：保证季度报告中财务报表的真实、准确、完整。 2 通化金马药业集团股份有限公司 2019 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | |-----------------------------------------------------|-----------------------------------|-------------------------|---------- ...

通化金马药业集团股份有限公司 2019 年半年度报告全文 通化金马药业集团股份有限公司 2019 年半年度报告 2019 年 08 月 1 通化金马药业集团股份有限公司 2019 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人战红君、主管会计工作负责人于军及会计机构负责人(会计主管 人员)耿兰声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本半年度报告中涉及未来计划、发展战略等前瞻性陈述，不构成公司对投 资者的实质承诺，敬请广大投资者注意投资风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 通化金马药业集团股份有限公司 2019 年半年度报告全文 目录 | --- | --- | |-------------------------------------------------------------------------------------|-------| | | | ...

通化金马药业集团股份有限公司 2018 年年度报告全文 通化金马药业集团股份有限公司 2018 年年度报告 2019 年 04 月 1 通化金马药业集团股份有限公司 2018 年年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人姬彦锋、主管会计工作负责人于军及会计机构负责人(会计主管 人员)耿兰声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本年度报告涉及公司未来发展展望、经营计划等前瞻性陈述，不构成对投 资者的实质承诺，请投资者认真阅读，注意投资风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 通化金马药业集团股份有限公司 2018 年年度报告全文 目录 | --- | |--------------------------------------------| | | | 第一节 重要提示、目录和释义 | | 第二节 公司简介和主要财务指标. | | 第三节 公司业务概要 ... ... ...